Published supplementary materials on fundraising. Combining third-party allotment to major shareholders and a Targeted Issue Program (TIP) to allocate funds for preparation of a U.S. Phase III for the acute spinal cord injury pipeline and strengthening manufacturing infrastructure. Set the 20th stock acquisition rights with two exercise price options (600 yen and 1,000 yen) and modification rights, assuming maximum dilution of 37.15%. Plan to execute future fundraising in phased and flexible manners. Allottees include Macquarie Bank Limited; net proceeds at this time are approximately 2.2 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4884-20261111-01.pdf","jir_short_summary":"Published supplementary materials on fundraising. Combining third-party allotment to major shareholders and a Targeted Issue Program (TIP) to allocate funds for preparation of a U.S. Phase III for the acute spinal cord injury pipeline and strengthening manufacturing infrastructure. Set the 20th stock acquisition rights with two exercise price options (600 yen and 1,000 yen) and modification rights, assuming maximum dilution of 37.15%. Plan to execute future fundraising in phased and flexible manners. Allottees include Macquarie Bank Limited; net proceeds at this time are approximately 2.2 billion yen.","jir_summary":"### Key Points of Fundraising\nKringle Pharma, Inc. is conducting fundraising focused on strengthening the late-stage development pipeline and preparing for a Phase III trial in the U.S. through a combination of third-party allotment and a TIP. Approximately 2.2 billion yen has been secured at this time, and the plan is to phase exercise of warrants with two exercise price options (600 yen and 1,000 yen). The design ensures continued support from two strategic shareholders including major shareholders and secures flexibility in capital policy by allotting to Macquarie Bank Limited.\n\n### Use of Funds and Impact\nFunds will be allocated to U.S. Phase III preparation for the acute spinal cord injury pipeline, establishment of manufacturing systems for recombinant human HGF protein drug substance, domestic drug substance manufacturing, and working capital. Utilizing the TIP enables additional fundraising during stock price appreciation, aiming to balance corporate value enhancement with shareholder value. Dilution is expected to be up to approximately 37%, and the structure is designed to secure future flexibility in capital policy.","jir_financial_highlights":"Estimated Net Proceeds: 2.2 hundred million yen (Unknown)\nUse of Funds \/ Allocation (each item): \u2460 678 million yen \u2461 640 million yen \u2462 310 million yen \u2463 577 million yen (Unknown)\nMaximum Dilution Rate: 37.15% (Based on combined fixed portion and potential shares)","jir_category":"","jir_hashtags":"#KringlePharma CapitalPolicy, #CapitalPolicy, #WarrantsTIP, #ThirdPartyAllotment","jir_key_figures":"Estimated Net Proceeds: 2.2 hundred million yen\n\u2460 678 million yen \u2461 640 million yen \u2462 310 million yen \u2463 577 million yen\nMaximum Dilution Rate: 37.15% (voting rights basis 37.19%)","jir_meta_title":"Kringle Pharma, Inc. Capital Policy and Fundraising Scheme Overview | November 2026","jir_meta_description":"Analysis of supplementary fundraising materials from Kringle Pharma, Inc. Summarizes capital policy combining third-party allotment and TIP, use of proceeds, dilution rates, allottees, and key points investors should know.","jir_og_title":"Kringle Pharma, Inc. Overview of Fundraising and Capital Policy Key Points","jir_og_description":"Overall picture of fundraising combining TIP warrants and third-party allotment as a capital policy. Summarizes uses, dilution, allottees, and other information directly relevant to investment decisions.","jir_og_image_url":"\/assets\/og\/company-capital_policy.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-149830","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n